A New Turning Point in Alzheimer's Drug Research

When our parents repeat themselves, we often just brush it off and say, 'It's okay.' But did you know that behind the scenes, significant changes are already occurring in the brain?

To this day, the exact cause of Alzheimer's disease remains unclear. For over 30 years, a protein called amyloid beta has been considered the main culprit, yet various new drugs aimed at removing it have not delivered the expected results. However, a research team from ETH Zurich in Switzerland has recently discovered a new clue to this puzzle.

The Discovery of the GRK2 Enzyme

The research team focused on an enzyme called GRK2. This enzyme is a regulatory protein that helps cells respond correctly to external signals and stress, and it is particularly active in the heart and brain neurons. The study found that abnormally aggregated GRK2 was abundant in the brains of Alzheimer's patients, a phenomenon also observed in Alzheimer's mouse models.

• Normal form of GRK2
• Abnormally aggregated GRK2

This abnormal GRK2 clumps together with proteins that act as entry points to the mitochondria, hindering the cell's energy production. Ultimately, this stresses the neurons, leading to a loss of function.

The Vicious Cycle of Dementia

The research team revealed that as the aggregation of GRK2 and mitochondrial dysfunction worsen, the accumulation of amyloid beta increases. This signifies that dementia forms a structure that accelerates its own deterioration. This vicious cycle is one of the reasons why Alzheimer's research is challenging and time-consuming.

A New Therapeutic Possibility: Compound 10

The research team identified Compound 10, a substance that inhibits GRK2 aggregation. In mouse experiments, this compound helped maintain neuronal function and extend survival periods. Furthermore, it showed positive results, including restored mitochondrial function and reduced amyloid beta deposition.

Professor Quitterer stated, "We have found a new target that operates through a completely different mechanism than existing Alzheimer's drugs," expressing hope that it could improve patients' quality of life when used in combination with other medications.

Future Research Directions

Although this research is still in the animal testing phase, it holds significant meaning as it opens a door that has been stubbornly shut for 30 years. We are beginning to find answers as to why new drugs haven't been as effective as expected. We look forward to its development into an actual therapeutic agent through clinical trials.